REG - Tristel PLC - Result of AGM

TristelAnnouncement

Yesterday 12:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20251211:nRSK2296La&default-theme=true

RNS Number : 2296L  Tristel PLC  11 December 2025

TRISTEL plc

("Tristel" or the "Company")

 

Result of AGM

 

Tristel plc (AIM: TSTL), the manufacturer of infection prevention products,
announces that at the Annual General Meeting ("AGM") held earlier today, all
resolutions were duly passed.

 

Resolution 1, which sought to receive and adopt the Company's annual accounts
for the financial year ended 30 June 2025, together with the Directors'
report, the Directors' remuneration report and the auditor's report on those
accounts, passed with 59% of votes cast. With respect to this resolution the
Company received notice from one of the proxy voting advisers that they were
recommending investors to vote against it, due to lack of a separate vote for
remuneration policy and the level of loss of office payment to a former
Director accompanied by limited disclosure.

 

Resolution 1 has been discussed with several of the institutional shareholders
and within the Board. The Board undertakes that it will ensure any necessary
future disclosure complies with best practice, along with committing to put
the remuneration policy to a separate vote at future AGMs, in line with QCA
guidance.

 

The Company would like to reiterate that it takes its shareholder
responsibilities seriously and has a clear focus on striving for governance
best practice, sharpening capital allocation and driving sustainable growth.

 

The results of the AGM will be made available on the Company's website:
https://tristelgroup.com/invest/annual-general-meeting-agm/
(https://tristelgroup.com/invest/annual-general-meeting-agm/)

 

For further information please contact:

 

 Tristel plc                                                                Via Walbrook PR
 Matt Sassone, Chief Executive Officer                                      www.investors.tristel.com (http://www.investors.tristel.com/)
 Anna Wasyl, Chief Financial Officer

 Walbrook PR Ltd                                                            Tel: 020 7933 8780 or tristel@walbrookpr.com
 Paul McManus / Lianne Applegarth / Anna Dunphy    Mob: 07980 541 893/ 07584 391 303/ 07876 741 001

 Cavendish Capital Markets Ltd                                              Tel: 020 7220 0500
 Geoff Nash / Callum Davidson / Trisyia Jamaludin (Corporate Finance)
 Sunila de Silva (Corporate Broking) / Louise Talbot (Sales)

 

 

About Tristel plc

 

Tristel plc is a global infection prevention company focussed on the
manufacture and supply of products using its unique proprietary chlorine
dioxide (ClO(2)) chemistry. The Company is a market leader in manual
decontamination of medical devices, supplying hospitals under the Tristel
(https://tristel.com/) brand, and under the Cache
(https://thecachecollection.com/) brand provides products for sporicidal
surface disinfection, a more sustainable alternative to commonly used
pre-wetted plastic wipes.

 

Tristel's head office and manufacturing facility is located in Snailwell, near
Cambridge, and operates globally employing approximately 270 people across 16
subsidiaries selling into 40+ countries. The Company targets double digit
revenue growth annually and an EBITDA margin of at least 25% and the business
is profitable, with no debt and has a progressive dividend policy.

 

The Company has been listed on the London Stock Exchange's AIM market since
2005 (AIM: TSTL).

 

For more information about Tristel's product range please visit:
https://tristel.com (https://tristel.com)

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  RAGFLFELFVLLLIE



            Copyright 2019 Regulatory News Service, all rights reserved